Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

BioGaia AB (publ)

BIOGYPNK
Healthcare
Drug Manufacturers - Specialty & Generic
$11.00
$0.00(0.00%)
U.S. Market opens in NaNh NaNm

BioGaia AB (publ) Fundamental Analysis

BioGaia AB (publ) (BIOGY) shows moderate financial fundamentals with a PE ratio of 30.35, profit margin of 21.64%, and ROE of 24.30%. The company generates $1.5B in annual revenue with moderate year-over-year growth of 9.73%.

Key Strengths

ROE24.30%
Operating Margin27.07%
Cash Position72.01%
PEG Ratio0.61
Current Ratio6.12

Areas of Concern

No major concerns flagged.
We analyze BIOGY's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 79.2/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.

Fundamental Health Score

B
79.2/100

We analyze BIOGY's fundamental strength across five key dimensions:

Efficiency Score

Excellent

BIOGY demonstrates superior asset utilization.

ROA > 10%
20.77%

Valuation Score

Moderate

BIOGY shows balanced valuation metrics.

PE < 25
30.35
PEG Ratio < 2
0.61

Growth Score

Moderate

BIOGY shows steady but slowing expansion.

Revenue Growth > 5%
9.73%
EPS Growth > 10%
-4.14%

Financial Health Score

Excellent

BIOGY maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
6.12

Profitability Score

Excellent

BIOGY achieves industry-leading margins.

ROE > 15%
24.30%
Net Margin ≥ 15%
21.64%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is BIOGY Expensive or Cheap?

P/E Ratio

BIOGY trades at 30.35 times earnings. This suggests a premium valuation.

30.35

PEG Ratio

When adjusting for growth, BIOGY's PEG of 0.61 indicates potential undervaluation.

0.61

Price to Book

The market values BioGaia AB (publ) at 7.66 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

7.66

EV/EBITDA

Enterprise value stands at 23.42 times EBITDA. This signals the market has high growth expectations.

23.42

How Well Does BIOGY Make Money?

Net Profit Margin

For every $100 in sales, BioGaia AB (publ) keeps $21.64 as profit after all expenses.

21.64%

Operating Margin

Core operations generate 27.07 in profit for every $100 in revenue, before interest and taxes.

27.07%

ROE

Management delivers $24.30 in profit for every $100 of shareholder equity.

24.30%

ROA

BioGaia AB (publ) generates $20.77 in profit for every $100 in assets, demonstrating efficient asset deployment.

20.77%

Following the Money - Real Cash Generation

Operating Cash Flow

BioGaia AB (publ) produces operating cash flow of $296.08M, showing steady but balanced cash generation.

$296.08M

Free Cash Flow

BioGaia AB (publ) generates strong free cash flow of $292.58M, providing ample flexibility for dividends, buybacks, or growth.

$292.58M

FCF Per Share

Each share generates $2.97 in free cash annually.

$2.97

FCF Yield

BIOGY converts 3.07% of its market value into free cash.

3.07%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

30.35

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.61

vs 25 benchmark

P/B Ratio

Price to book value ratio

7.66

vs 25 benchmark

P/S Ratio

Price to sales ratio

6.39

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

6.12

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.24

vs 25 benchmark

ROA

Return on assets percentage

0.21

vs 25 benchmark

ROCE

Return on capital employed

0.30

vs 25 benchmark

How BIOGY Stacks Against Its Sector Peers

MetricBIOGY ValueSector AveragePerformance
P/E Ratio30.3529.78 Neutral
ROE24.30%792.00% Weak
Net Margin21.64%-23280.00% (disorted) Strong
Debt/Equity0.000.25 Strong (Low Leverage)
Current Ratio6.124.60 Strong Liquidity
ROA20.77%-18077.00% (disorted) Strong

BIOGY outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews BioGaia AB (publ)'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

58.80%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

60.86%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

116.48%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ